EDV-plasmid-spike-GC
/ EnGeneIC
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 05, 2025
COVID-EDV IC/ENG 14: A study of the safety of EDV nanocells packaged with spike-protein plasmid and glycolipid as a COVID-19 vaccine in immunocompromised patients.
(ANZCTR)
- P1/2 | N=100 | Terminated | Sponsor: EnGeneIC Pty Limited | Recruiting ➔ Terminated
Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
December 01, 2023
A study of the safety of EDV nanocells packaged with spike-protein plasmid and glycolipid as a COVID-19 vaccine in immunocompromised patients.
(ANZCTR)
- P1/2 | N=100 | Recruiting | Sponsor: EnGeneIC Pty Limited
New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8 • CRP
September 04, 2023
A study of the safety of EDV nanocells packaged with spike-protein plasmid and glycolipid as a COVID-19 vaccine in immunocompromised patients.
(ANZCTR)
- P1/2 | N=100 | Recruiting | Sponsor: EnGeneIC Pty Limited | Initiation date: Apr 2000 ➔ Apr 2023
Trial initiation date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8 • CRP
August 12, 2023
A study of the safety of EDV nanocells packaged with spike-protein plasmid and glycolipid as a COVID-19 vaccine in immunocompromised patients.
(ANZCTR)
- P1/2 | N=100 | Recruiting | Sponsor: EnGeneIC Pty Limited
New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8 • CRP
August 27, 2021
A study of the safety of EDV nanocells packaged with spike-protein plasmid and glycolipid as a COVID-19 vaccine in healthy volunteers.
(ANZCTR)
- P1; N=18; Recruiting; Sponsor: EnGeneIC Pty Limited
Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8 • CRP
1 to 5
Of
5
Go to page
1